Gland Pharma Limited — Investor Meet, 17-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Gland Pharma kicked off FY27 with robust performance: revenue up 20% YoY (15% constant currency) to ₹1,800.3 Cr. Adjusted EBITDA hit ₹510.2 Cr (28% margin), and PAT surged 47% YoY to ₹317 Cr. Growth was driven by strong CDMO (50% of revenue) and B2B segments, plus new launches. Key strategic wins include a manufacturing pact for 55 injectable SKUs for a global pharma, projecting $90-100M revenue from CY2029. Partnerships for sterile APIs and a niche liposomal product (revenue from FY30) bolster the future pipeline. Company plans ₹550 Cr capex this year. Management projects 15-20% CAGR (constant currency) over 4-5 years, targeting 30% near-term EBITDA. Confident outlook.